jRCTc030190081招募中不适用
Treatment with chemotherapy and dendritic cells pulsed with neoantigen-specific epitopes for pancreatic cancer. (PK-neoantigen-DCtest)
未提供0 个研究点目标入组 10 人开始时间: 2020年3月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10
- 主要终点
- safety and toxicity
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Human leukocyte antigen (HLA)-A*02:01- or A*24:02-positive patients.
- •Patients with histologically or cytologically confirmed locally advanced or metastatic pancreatic cancer, or recurrent disease after surgery.
- •Patients with ages between 20 and 75 years.
- •Karnofsky performance status (KPS) of 80% to 100%.
- •Patients with a KPS of 70% were also included but only if KPS was decreased by poorly controlled cancerous pain at enrollment.
- •Patients had adequate hematologic, hepatic, and renal function.
- •Patients had a life expectancy of at least 3 months.
- •All patients provided written informed consent.
排除标准
- •The exclusion criteria were pregnancy, serious infections, severe underlying disease, severe allergic disease, and a judgment of unsuitability by the principal investigator.
结局指标
主要结局
safety and toxicity
The assessment of the safety and toxicity of the combination therapy based on the Common Terminology Criteria for Adverse Events (CTCAE)
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Adoptive immune therapy of chemotherapy-refractory CMV-infection with Streptamer-selected T-cells after allogeneic bone marrow- or peripheral blood stem cell transplantatioCytomegaloviral disease, unspecifiedB25.9DRKS00000205Stage Pharmaceuticals GmbH30
进行中（未招募）
不适用
Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial - AIT-CMV-Stage-01-chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapyEUCTR2006-006146-34-DEStage Pharmaceuticals GmbH30
尚未招募
不适用
Personalized cancer immunotherapy with neoantigen peptide-pulsed dendritic cellsEsophageal cancerjRCT2033240683NPT CO., LTD.12
尚未招募
不适用
Towards the development of neo-antigen-targeted, personalized immunotherapies for advanced colorectal cancer patients.Colorectal carcinomaColorectal cancer10017990NL-OMON42438eids Universitair Medisch Centrum50
进行中（未招募）
1 期
Study of chemotherapy and immunotherapy before and after surgery inpatients with non-small cell lung cancer whose tumor is located in theupper part of the lungsResectable Non-small cell lung cancer Pancoast tumorMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10033572Term: Pancoast's tumour Class: 100000004864CTIS2024-512359-19-00Fundacion GECP40